Investment Thesis
Ainos is a financially distressed pharmaceutical company experiencing severe operational deterioration with revenue collapsing 83% YoY while burning cash at an alarming rate. The company's negative operating margin of -8574.8% and free cash flow of -3.8M indicate unsustainable operations with minimal revenue generation relative to expenses. With only 1.1M in cash and ongoing cash burn, the company faces imminent liquidity crisis unless it can dramatically reverse its business trajectory.
Strengths
- Positive gross margin of 82.6% suggests potential product profitability if revenue scales
- Current ratio of 2.96x provides short-term liquidity cushion
- Zero long-term debt eliminates refinancing risk
Risks
- Revenue collapsed 83% YoY with only 113K in trailing revenue, indicating complete loss of market demand
- Operating cash flow of -3.8M with only 1.1M in cash provides less than 3 months of runway at current burn rate
- Negative ROE of -102.6% and ROA of -45.4% demonstrate value destruction and operational failure
- Operating margin of -8574.8% indicates the company cannot support its cost structure with current revenue levels
- Dramatic EPS deterioration to -2.61 despite modest YoY improvement signals ongoing value destruction
Key Metrics to Watch
- Monthly cash burn rate and cash runway duration
- Revenue stabilization and return to growth trajectory
- Operating expense reduction initiatives or restructuring plans
- Product pipeline clinical trial progress and commercialization timelines
Financial Metrics
Revenue
113.0K
Net Income
-10.3M
EPS (Diluted)
$-2.61
Free Cash Flow
-3.8M
Total Assets
22.7M
Cash
1.1M
Profitability Ratios
Gross Margin
82.6%
Operating Margin
-8,574.8%
Net Margin
-9,114.5%
ROE
-102.6%
ROA
-45.4%
FCF Margin
-3,358.0%
Balance Sheet & Liquidity
Current Ratio
2.96x
Quick Ratio
2.67x
Debt/Equity
0.00x
Debt/Assets
55.7%
Interest Coverage
-199.05x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-19T17:47:14.896602 |
Data as of: 2025-09-30 |
Powered by Claude AI